^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN

Published date:
05/11/2023
Excerpt:
To evaluate the prognostic impact of the MRD status in pts 18-70 years with FLT3-ITD+ AML enrolled on the AMLSG16-10 trial (NCT01477606) combining intensive chemotherapy with midostaurin...Concurrent NPM1mut correlated with deeper molecular responses and higher rates of MRD-.
Secondary therapy:
Chemotherapy
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

Published date:
05/05/2023
Excerpt:
We analyzed the impact of midostaurin in 227 FLT3mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098)….The effect of midostaurin was evident in NPM1mut patients (n = 151), with 2-yr OS of 72% (exposed) vs 50% (naive) patients (p = 0.011)....In conclusion, this study highlights the improved outcome of FLT3mut AML fit patients with the incorporation of midostaurin.
DOI:
10.1038/s41408-023-00839-1